1 / 2

TRODELVY FOR HER2 METASTATIC BREAST CANCER | 9310090915

Healthcare professionals recommend administering Trodelvy for treating patients who have metastatic triple-negative breast cancer and metastatic urothelial cancer (mUC). This medicine comes in single-dose vials in 180 mg for intravenous administration. The common side-effects of Trodelvy 180 mg are: neutropenia, nausea, diarrhea, fatigue, alopecia, anemia, vomiting, constipation, decreased appetite, rash and abdominal pain. The active ingredient in the medicine is Sacituzumab govitecan-hziy with inactive ingredients 2-(N-morpholino) ethane sulfonic acid (MES), polysorbate 80 and trehalose dihy

import1
Download Presentation

TRODELVY FOR HER2 METASTATIC BREAST CANCER | 9310090915

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HER2 METASTATIC BREAST CANCER & ITS NEW TREATMENT HER2-positive metastatic breast cancer is a subtype of breast cancer where the cancer cells overexpress the HER2 protein, leading to more aggressive cancer growth and increased risk of metastasis. There are several treatments available for HER2-positive metastatic breast cancer, including chemotherapy, targeted therapy, hormone therapy, and immunotherapy. One new treatment option is Tucatinib (Tukysa), which was approved by the US FDA in 2020. Tucatinib is a small molecule tyrosine kinase inhibitor that targets HER2, and it has shown promising results in clinical trials. In a phase 3 trial, the addition of tucatinib to standard treatment (trastuzumab and capecitabine) resulted in a significant improvement in progression-free survival and overall survival compared to standard treatment alone. Other newer treatments that have been approved for HER2-positive metastatic breast cancer include trastuzumab deruxtecan (Enhertu), a HER2-targeted antibody-drug conjugate, and fam- trastuzumab deruxtecan-nxki (Zynlonta), another antibody-drug conjugate. Both drugs have shown promising results in clinical trials and have been approved for patients who have received at least two prior anti-HER2 treatments. It's important to note that the best treatment for HER2-positive metastatic breast cancer will depend on the individual patient's medical history, tumor characteristics, and other factors. Patients should discuss all treatment options with their healthcare providers to make an informed decision about their care.

  2. Source - https://indiangenericmedicine.over-blog.com/her2-metastatic-breast-cancer-its-new- treatment.html

More Related